Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939679 | 0.89 | MRGPRX4 (0.66) | RAB9AKMT2ANPC1MAPTMEN1 | |
| SCHEMBL883130 | 0.85 | TNKS (0.60) | RAB9AKMT2ANPC1MAPTMEN1 | |
| SCHEMBL27149873 | 0.84 | L3MBTL1 (0.55) | RAB9AKMT2ANPC1MEN1MRGPRX4 | |
| SCHEMBL11508522 | 0.84 | MAPT (0.63) | RAB9AKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL19898170 | 0.84 | TDP1 (0.56) | KMT2AMAPTMEN1CA1CA2 | |
| SCHEMBL28294866 | 0.83 | SRD5A2 (0.58) | KMT2AMEN1ALDH1A1POLBMGLL | |
| SCHEMBL21288599 | 0.83 | KMT2A (0.64) | RAB9AKMT2ANPC1MAPTMEN1 | |
| SCHEMBL30147521 | 0.83 | HPGD (0.67) | RAB9ANPC1MRGPRX4ALDH1A1KDM4E | |
| SCHEMBL8569015 | 0.83 | CA1 (0.55) | RAB9AKMT2ANPC1MAPTMEN1 | |
| SCHEMBL27480274 | 0.83 | HSD17B1 (0.59) | RAB9ANPC1MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| CN-103261156-A | New compounds for the treatment of neurodegenerative diseases | LEUVEN K U RES & DEV | 2013-08-21 | — | — | CN | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | RAB9A 513/4885KMT2A 3795/4885NPC1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.